Literature DB >> 12904063

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.

Masahiro Nomura1, Takahiro Tanase, Tomohiro Ide, Masaki Tsunoda, Masahiro Suzuki, Hideharu Uchiki, Koji Murakami, Hiroyuki Miyachi.   

Abstract

Substituted phenylpropanoic acid derivatives were prepared as part of a search for subtype-selective human peroxisome proliferator activated receptor alpha (PPARalpha) activators. Structure-activity relationship studies indicated that the nature and the stereochemistry of the substituent at the alpha-position of the head part containing the carboxyl group, the distance between the carboxyl group and the central benzene ring, the linking group between the central benzene ring and the distal benzene ring, and the substituent at the distal hydrophobic tail part of the molecule all play key roles in determining the potency and selectivity of PPAR subtype transactivation. This study has led to the identification of potent and human PPARalpha selective optically active alpha-alkylphenylpropanoic acid derivatives, which will be useful not only as pharmacological tools to investigate the physiology and pathophysiology of PPARalpha but also as candidate drugs for the treatment of altered metabolic homeostasis, such as dyslipidemia, obesity, and diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904063     DOI: 10.1021/jm0205144

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?

Authors:  Günther Weindl; Monika Schäfer-Korting; Martin Schaller; Hans Christian Korting
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Discovery of peroxisome proliferator-activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line.

Authors:  Keisuke Tachibana; Tomohiro Yuzuriha; Ryotaro Tabata; Syohei Fukuda; Takashi Maegawa; Rika Takahashi; Keiichi Tanimoto; Hirofumi Tsujino; Kazuto Nunomura; Bangzhong Lin; Yoshiharu Matsuura; Toshiya Tanaka; Takao Hamakubo; Juro Sakai; Tatsuhiko Kodama; Tadayuki Kobayashi; Kenji Ishimoto; Hiroyuki Miyachi; Takefumi Doi
Journal:  J Biol Chem       Date:  2018-05-15       Impact factor: 5.157

Review 3.  Multi-Target Approaches in Metabolic Syndrome.

Authors:  Felix F Lillich; John D Imig; Ewgenij Proschak
Journal:  Front Pharmacol       Date:  2021-03-12       Impact factor: 5.810

4.  Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.

Authors:  Xiaozheng Dou; Dinesh Nath; Henry Shin; Elmar Nurmemmedov; Philip C Bourne; Jian-Xing Ma; Adam S Duerfeldt
Journal:  J Med Chem       Date:  2020-03-10       Impact factor: 8.039

5.  Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template.

Authors:  Hiroyuki Miyachi; Yuichi Hashimoto
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.